Abstract：Sepsis is a dysregulated host response caused by infection, resulting in a life-threatening organ dysfunctional disease with rapid progression and high mortality. Blood culture is the gold standard for its diagnosis, but it is time-consuming. Therefore, specific auxiliary diagnosis markers have become the focus of clinicians' attention in diagnosing sepsis. Various types of early biologic diagnostic markers for sepsis are now available, which are of great clinical values for clinical diagnosis and treatment of sepsis, prognosis of the disease and evaluation of efficacy. This study reviews the research progress on early diagnostic biomarkers for sepsis, with a view to providing new evidence for the early clinical diagnosis and treatment of sepsis.
范俊杰, 余闻静, 肖洪, 刘鑫, 郑江, 龙宇鹏. 脓毒症早期生物诊断标志物研究进展[J]. 实用预防医学, 2022, 29(12): 1545-1550.
FAN Jun-jie, YU Wen-jing, XIAO Hong, LIU Xin, ZHENG Jiang, LONG Yu-peng. Research progress on early diagnostic biomarkers for sepsis. , 2022, 29(12): 1545-1550.
[1] Katoch T,Singh A,Suri V,et al. Diagnostic performance of biomarkers in maternal sepsis: a prospective observational study[J]. Int J Gynaecol Obstet, 2020, 154(2):312-317. [2] Rudd KE,Johnson SC,Agesa KM,et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study[J]. Lancet, 2020, 395(10219):200-211. [3] Reinhart K, Daniels R, Kissoon N, et al. Recognizing sepsis as a global health priority-A WHO resolution[J]. N Engl J Med, 2017, 377(5):414-417. [4] Asner SA, Desgranges F, Schrijver IT, et al. Impact of the timeliness of antibiotic therapy on the outcome of patients with sepsis and septic shock[J]. J Infect, 2021, 82(5):125-134. [5] Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock[J]. Lancet, 2018, 392(10141):75-87. [6] Mierzchaa-Pasierb M,Lipińska-Gediga M. Sepsis diagnosis and monitoring-procalcitonin as standard, but what next?[J]. Anaesthesiol Intensive Ther, 2019, 51(4):299-305. [7] 朱孟沙, 张贵英, 赵清娟, 等. Presepsin在脓毒症早期诊断和预后评估中应用价值[J].中华实用诊断与治疗杂志, 2020, 34(2):152-154. [8] Singer M,Deutschman CS,Seymour CW,et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8):801-810. [9] 中国医师协会急诊医师分会,中国研究型医院学会休克与脓毒症专业委员会. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 感染、炎症、修复, 2019, 20(1):3-22. [10] Venkataranganayaka AK, Kenihithlu MG. Bacterial lipoproteins in sepsis[J]. Immunobiology, 2021, 226(5):152128. [11] 慕婉晴, 顾国嵘. 降钙素原(PCT)在脓毒症临床诊断治疗中作用的研究进展[J]. 复旦学报(医学版), 2019, 46(1):103-107. [12] 中国医药教育协会感染疾病专业委员会. 感染相关生物标志物临床意义解读专家共识[J]. 中华结核和呼吸杂志, 2017, 40(4):243-257. [13] Giannakopoulos K,Hoffmann U,Ansari U,et al. The use of biomarkers in sepsis: a systematic review[J]. Curr Pharm Biotechnol, 2017, 18(6):499-507. [14] Wu F,Hou XQ,Sun RR,et al. The predictive value of joint detection of serum amyloid protein A, PCT, and Hs-CRP in the diagnosis and efficacy of neonatal septicemia[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13):5904-5911. [15] 辛海亮, 吴倩, 张园园.血流感染致脓毒症患者血清降钙素原、前列腺素-2、C反应蛋白水平变化及意义[J].实用预防医学, 2018,25(11):1394-1396. [16] Oliveira CF, Botoni FA, Oliveira CRA, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial[J]. Crit Care Med, 2013, 41(10):2336-2343. [17] Porte R, Davoudian S, Asgari F, et al. The long pentraxin PTX3 as a humoral innate immunity functional player and biomarker of infections and sepsis[J]. Front Immunol, 2019, 10:794. [18] Ciancarella V,Lembo-Fazio L,Paciello I,et al. Role of a fluid-phase PRR in fighting an intracellular pathogen: PTX3 in Shigella infection[J]. PLoS Pathog, 2018, 14: e1007469. [19] Ketter P, Yu JJ, Cap AP, et al. Pentraxin 3: an immune modulator of infection and useful marker for disease severity assessment in sepsis[J]. Expert Rev Clin Immunol, 2016, 12(5):501-507. [20] Lee YT, Gong M, Chau A, et al. Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: a systematic review and meta-analysis[J]. J Infect, 2018, 76(1):1-10. [21] Hu C, Zhou Y, Liu C, et al. Pentraxin-3, procalcitonin and lactate as prognostic markers in patients with sepsis and septic shock[J]. Oncotarget, 2018, 9: 5125-5136. [22] Semeraro F, Ammollo CT, Caironi P, et al. D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis[J]. Blood Transfus, 2020, 18(4):304-311. [23] 赵茜, 李剑, 李素彦, 等.降钙素原及D-二聚体检测对急诊脓毒症患者病情及预后的预测价值分析[J]. 解放军医药杂志, 2020, 32(11):67-70. [24] Meini S, Sozio E, Bertolino G, et al. D-dimer as biomarker for early prediction of clinical outcomes in patients with severe invasive infections due to Streptococcus pneumoniae and Neisseria meningitidis[J]. Front Med, 2021, 8:627830. [25] Semeraro F,Colucci M,Caironi P,et al. Platelet drop and fibrinolytic shutdown in patients with sepsis[J]. Crit Care Med, 2018, 46:e221-e228. [26] Semeraro F, Ammollo CT, Caironi P, et al. Low D-dimer levels in sepsis: good or bad? [J]. Thromb Res, 2019, 174: 13-15. [27] Pietrasanta C, Ronchi A, Vener C, et al. Presepsin (Soluble CD14 Subtype) as an early marker of neonatal sepsis and septic shock: a prospective diagnostic trial[J]. Antibiotics(Basel), 2021, 10(5):580. [28] Ozkan S, Kahveci U, Hur I, et al. Prognostic importance of serum presepsin level in pneumonia focal sepsis and its relationship with other biomarkers and clinical severity scores[J]. Saudi Med J, 2021, 42(9):994-1001. [29] Velissaris D, Zareifopoulos N, Karamouzos V, et al. Presepsin as a diagnostic and prognostic biomarker in sepsis[J]. Cureus, 2021, 13(5):e15019. [30] Chenevier-Gobeaux C, Borderie D, Weiss N, et al. Presepsin (sCD14-ST), an innate immune response marker in sepsis[J]. Clin Chim Acta, 2015, 450: 97-103. [31] Hashem HE, Abdel Halim RM, El Masry SA, et al. The utility of neutrophil CD64 and presepsin as diagnostic, prognostic, and monitoring biomarkers in neonatal sepsis[J]. Int J Microbiol, 2020, 2020: 8814892. [32] Vincent JL,Quintairos ESA,Couto L,et al. The value of blood lactate kinetics in critically ill patients: a systematic review[J]. Crit Care, 2016, 20(1):257. [33] Nolt B, Tu F, Wang X, et al. Lactate and immunosuppression in sepsis[J]. Shock, 2018,49(2):120-125. [34] Hoque R,Farooq A,Ghani A,et al. Lactate reduces liver and pancreatic injury in Toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity[J]. Gastroenterology, 2014, 146(7):1763-1774. [35] 骆付丽, 华维, 钱民, 等. T淋巴细胞亚群及Th1/Th2细胞因子谱早期鉴别细菌尿源性脓毒症[J]. 中华医院感染学杂志, 2021, 31(4):502-506. [36] Huang H, Wang S, Jiang T, et al. High levels of circulatiog GM-CSF+CD4+T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study[J]. Cell Mol Immunol, 2019, 16(6):602-610. [37] Chen J, Xuan J, Gu YT, et al. Celastrol reduces IL-1β induced matrix catabolism, oxidative stress and inflammation in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration in vivo[J]. Biomed Pharmacother, 2017, 91: 208-219. [38] Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229):1054-1062. [39] Sharma A, Nguyen P, Taha M, et al. Sepsis hospitalizations with versus without cancer: epidemiology, outcomes, and trends in nationwide analysis from 2008 to 2017[J]. Am J Clin Oncol, 2021,44(10):505-511. [40] Zhou Y, Yang Y, Pappas D. Microfluidic chips for sepsis diagnosis[J]. Methods Mol Biol, 2021, 2321: 207-219. [41] Bülow S,Heyd R,Toelge M,et al. Lipopolysaccharide binding protein and bactericidal/permeability-increasing protein as biomarkers for invasive pulmonary aspergillosis[J]. J Fungi, 2020, 6(4):304. [42] Kudoh K,Mizukami H,Itabashi C,et al. Lipopolysaccharide-binding protein is a distinctive biomarker of abnormal pain threshold in the general Japanese population[J]. BMJ Open Diabetes Res Care, 2020, 8(1):e001739. [43] Tian R, Chen X, Yang C, et al. Serum heparin-binding protein as a potential biomarker to distinguish adult-onset still's disease from sepsis[J]. Front Immunol, 2021, 12: 654811. [44] Zhou YX, Liu LH, Tao SF, et al. Parthanatos and its associated components: promising therapeutic targets for cancer[J]. Pharmacol Research, 2020, 163: 105299. [45] Utispan K, Koontongkaew S. Macrophage migration inhibitory factor modulates proliferation, cell cycle, and apoptotic activity in head and neck cancer cell lines[J]. J Dent Sci, 2020, 16(1):342-348. [46] Ma M, Tao L, Liu A, et al. Macrophage migration inhibitory factor-794 CATT microsatellite polymorphism and susceptibility of tuberculosis: a meta-analysis[J]. Biosci Rep, 2018, 38(4):BSR20171626. [47] Chao CH,Chen HR,Chuang YC,et al. Macrophage migration inhibitory factor-induced autophagy contributes to thrombin-triggered endothelial hyperpermeability in sepsis[J]. Shock, 2018, 50(1):103-111. [48] Toldi J, Nemeth D, Hegyi P, et al. Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials[J]. Sci Rep, 2021, 11(1):8051. [49] Chen L, Zhang RX, Zhu L, et al. Correlation of microRNA-146a/b with disease risk, biochemical indices, inflammatory cytokines, overall disease severity, and prognosis of sepsis[J]. Medicine, 2020, 99(22):e19754. [50] 马海艳, 刘学文, 付盈菊, 等. 脓毒症患者外周血miR-326与miR-370-3p表达及其意义[J]. 中华医院感染学杂志, 2021, 31(4):481-485. [51] Sun B, Guo S. miR-486-5p serves as a diagnostic biomarker for sepsis and its predictive value for clinical outcomes[J]. J Inflamm Res, 2021, 14: 3687-3695. [52] Singh KK, Matkar PN, Muhammad S, et al. Investigation of novel LPS-induced differentially expressed long non-coding RNAs in endothelial cells[J].Mol Cell Biochem,2016,421:157-168. [53] Hashemian SM, Pourhanifeh MH, Fadaei S, et al. Non-coding RNAs and exosomes: their role in the pathogenesis of sepsis[J]. Mol Ther Nucleic Acids, 2020, 21: 51-74. [54] Khan HN, Brands X, Aufiero S, et al. The circular RNA landscape in specific peripheral blood mononuclear cells of critically ill patients with sepsis[J]. Crit Care, 2020, 24(1):423. [55] Real JM, Ferreira LRP, Esteves GH, et al. Exosomes from patients with septic shock convey miRNAs related to inflammation and cell cycle regulation: new signaling pathways in sepsis? [J].Crit Care, 2018, 22(1):68. [56] Alexander M,Hu R,Runtsch MC,et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin[J].Nat Commun,2015, 6:7321.
2022, Vol. 29 
